Skip to content
Search

Latest Stories

Omnicell secures deal with Hanmi Pharmaceutical to distribute new dispensing automation in Britain

Omnicell has expanded it existing range of automated medicines management and adherence solutions by entering into an agreement with Hanmi Pharm to distribute innovative tools across the UK’s retail pharmacy market.


The American healthcare technology company says the deal is "in line with Omnicell’s vision and appreciation that the retail pharmacy market wants choice through a more agnostic approach to automated medication adherence solutions."

The South Korean Hanmi Pharm-owned JVM model will support both blister and pouch adherence with the same level of detail and infrastructure Omnicell offers for its full range of solutions.

The model offers a flexible portfolio of hardware – from small desktop to large-scale models capable of handling between 300 to 576 cartridges – enabling it to meet the varying demands of pharmacies and allowing them to scale up or down models to suit their requirements.

“The JVM range of products provides an exceptional new offering for a variety of budgets across the retail pharmacy market, which further demonstrates Omnicell’s commitment to understanding and meeting the needs of our clients,” said Sara Dalmasso, general manager and vice president of Omnicell International.

“The last 18-24 months have placed immense pressure on the sector and this is another step in helping to make the day-to-day working lives of pharmacists easier and more efficient, and ultimately freeing up their valuable time to focus more on face-to-face patient interaction and care.”

The agreement is expected to expand Omnicell’s existing automated medication adherence solutions, while making it more accessible to different users.

Cyrus Hodivala, sales director, UK and Ireland, at Omnicell International, adds: “It is important for us to be constantly evolving our solutions in line with the changing dynamics of the retail pharmacy sector. Joining forces with Hamni Pharm – a leading, global pharmaceutical company – provides a welcome expansion of Omnicell’s portfolio for the UK market.

“With a shared and comprehensive expertise in the automation field, we are confident the new partnership will ensure Omnicell remains at the forefront of automation solutions. By enabling pharmacists to easily scale their business, our solutions will result in immediate improvements in medication adherence and patient outcomes.”

In January, Omnicell acquired Hub and Spoke Innovations.

More For You

Youth vaping : project to examine health impacts on children

Youth vaping : project to examine health impacts on children

Youth vaping: £62M research project to examine health impacts on children

The UK government has announced a £62 million research project to investigate the long-term health effects of vaping on young people, alongside wider influences on adolescent health and wellbeing.

Keep ReadingShow less
David Thomas Steps In as NPA’s New Wales Representative
Five NPA members are contesting for the remaining position in England (gettyimages)

NPA board update: David Thomas succeeds Raj Aggarwal OBE

Five NPA members are contesting for the remaining position in England

David Thomas, owner of LT Chemists in Newport, will replace Raj Aggarwal OBE as the next National Pharmacy Association (NPA) board member for Wales, following an uncontested election this month.

Keep ReadingShow less
Public Policy Projects calls for better use of community pharmacy skill mix to improve medicines adherence
Non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed. (gettyimages)

Leverage pharmacy skill mix to improve medicines adherence - report suggests

The report also suggested expanding the community pharmacy contractual framework to enable community pharmacy to deliver medicines reviews

Pharmacy technicians and assistants should be enabled to talk to patients about their medications to improve medicines adherence, a new report has recommended.

Keep ReadingShow less
Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Kinnock confirms that an announcement on the 2025/26 GP contract would be made before April 2025

The 2025/26 pharmacy contract consultation will include a review of the medicine margin and reimbursement arrangements, health and care minister Stephen Kinnock has confirmed.

Keep ReadingShow less
NPA urges immediate release of pharmacy funding crises review
Underfunding has forced record numbers of pharmacy closures (gettyimages)

Suppressing pharmacy funding crisis analysis would be ‘outrageous’, warns NPA

The NPA fears the report won’t be published until pharmacy funding consultations conclude, while CPE states there is no set timeline for finalising negotiations.

The National Pharmacy Association (NPA) has called on the NHS and the Department of Health to immediately publish the government-commissioned analysis of pharmacy underfunding and reveal the true scale of the crisis.

Keep ReadingShow less